• Briacell Therapeutics added NYU Langone Health’s Perlmutter Cancer Center as a clinical site for its pivotal Phase 3 Bria-ABC trial in advanced metastatic breast cancer.
• Trial evaluates Bria-IMT with an immune checkpoint inhibitor versus physician’s choice, aiming to show improved overall survival.
• No trial results were presented; interim results are expected in coming months, with analysis triggered once 144 deaths have occurred.
• Program holds FDA Fast Track designation, supporting a faster development path if the study reads out positively.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070730PRIMZONEFULLFEED9714883) on May 07, 2026, and is solely responsible for the information contained therein.